AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00355147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self Management
Description: Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
Study NCT00355147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Group
Description: Received Phone Calls from Staff to Control for Attention
Study NCT02288091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
Study NCT02587507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Individuals will consume the HFHC meal with 500mL of orange juice.
Study NCT02587507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Individuals will consume the HFHC meal with 500mL of water.
Study NCT02587507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water with glucose
Description: Individuals will consume the HFHC meal with 500mL of water with glucose.
Study NCT02223936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: group exposed
Description: Assessment by Brunet Lezine scale
Study NCT02223936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Not exposed group
Study NCT00438607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIIB014
Description: oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
Study NCT00438607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for MTD or MTD-1
Study NCT01387711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (Ingenol mebutat Gel, 0.05 %)
Description: All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
Study NCT02475135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
Study NCT02475135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: A tablet containing Darunavir (DRV) 800 mg will be administered.
Study NCT02475135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir alafenamide (FTC/TAF)
Description: A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
Study NCT02475135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: A tablet containing cobicistat (COBI) 150 mg will be administered.
Study NCT02475135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat Breakfast
Description: High-fat breakfast will be administered.
Study NCT02475135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Regular Breakfast
Description: Standardized regular breakfast will administered.
Study NCT01450202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: bowel insufflation gas
Description: air insufflation, during colonoscopy and esophagogastroduodenoscopy
Study NCT01450202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bowel insufflation gas
Description: CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
Study NCT00466102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
Study NCT00466102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets are taken once daily during study therapy
Study NCT03582605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: see previous descriptions
Study NCT03582605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: see previous descriptions
Study NCT01426243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL)
Study NCT01426243 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL)
Study NCT03577158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop controller with exercise mitigation module
Description: Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study NCT03577158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop controller with exercise mitigation module
Description: Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study NCT03577158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop controller without exercise mitigation module
Description: On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study NCT01643018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
Study NCT01643018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: -open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
Study NCT01287416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Suicide Intervention Skills Training
Description: Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
Study NCT01287416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience Retreat
Description: The Resilience Retreat is a 2-day, 14 hour session
Study NCT03039088 — intervention group
Intervention type: OTHER
Intervention: Follow-up after 12 weeks after TNF alpha blockers initiation
Study NCT04659681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .
Description: PVI probe attached to finger in PVI Group
Study NCT04659681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given
Description: Placement of central venous catheter
Study NCT00963183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Study NCT00963183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose.
Study NCT04426409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tarivid ointment
Description: Vaseline ointment is applied to both noses.
Study NCT01369277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
Study NCT01658124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01658124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02593526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Diuretic
Study NCT01369277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose administration of matching placebo in tablet formulation at the fasted state
Study NCT01369277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
Study NCT02593526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Dialysate
Description: Cool dialysate (35°C)
Study NCT02710071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 5mg then nebivolol 10 mg
Study NCT02710071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
Study NCT01872143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
Study NCT03424291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus chemoradiation
Description: Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
Study NCT01270048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mild-ex-gwarip
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study NCT01270048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study NCT01136538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study NCT01136538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study NCT00863525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
Study NCT00863525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
Study NCT03290534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaSheet
Description: implanting CivaSheet for localized radiation dose delivery
Study NCT02696811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White carrots
Description: White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
Study NCT02696811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat biscuits
Description: The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
Study NCT03104790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)
Description: live attenuated influenza vaccine (LAIV)
Study NCT02729896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab [TECENTRIQ]
Description: Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment.
Study NCT02729896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
Study NCT02729896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
Study NCT00943150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
Study NCT00943150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: The scalpel and electrocautery will be used for the abdominoplasty procedure.
Study NCT03328871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 Laser
Description: Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
Study NCT03328871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: Nanofat grafting will be applied once every three months for 2 times.
Study NCT02729896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
Study NCT00372788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: oral vial
Study NCT00372788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: oral
Study NCT04578470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
Study NCT04578470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets daily for 13weeks then 1 tablet daily for13 weeks
Study NCT03328871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.
Study NCT01663285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Cisplatin and Gemcitabine
Description: Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
Study NCT01913535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CERC-501
Description: Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study NCT01913535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CERC-501
Description: Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study NCT01913535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study NCT01913535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Study NCT02103192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Oxidant Drink
Study NCT01101009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril + amlodipine + if necessary, hydrochlorothiazide
Description: Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Study NCT01101009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Description: olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Study NCT01721525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Description: Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
Study NCT02028000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insorb staples skin closure
Description: Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
Study NCT02028000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl skin closure
Description: Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
Study NCT02028000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl skin closure
Description: Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.